- Home
- CLRB vs QCLS Comparison
CLRB vs QCLS Comparison
Compare CLRB & QCLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- QCLS
- Stock Information
- Founded
- CLRB 2002
- QCLS 2014
- Country
- CLRB United States
- QCLS United States
- Employees
- CLRB N/A
- QCLS N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- QCLS Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CLRB Health Care
- QCLS Health Care
- Exchange
- CLRB Nasdaq
- QCLS Nasdaq
- Market Cap
- CLRB 12.8M
- QCLS 12.5M
- IPO Year
- CLRB N/A
- QCLS N/A
- Fundamental
- Price
- CLRB $2.88
- QCLS $3.80
- Analyst Decision
- CLRB Hold
- QCLS
- Analyst Count
- CLRB 2
- QCLS 0
- Target Price
- CLRB N/A
- QCLS N/A
- AVG Volume (30 Days)
- CLRB 90.4K
- QCLS 820.0K
- Earning Date
- CLRB 11-13-2025
- QCLS 11-19-2025
- Dividend Yield
- CLRB N/A
- QCLS N/A
- EPS Growth
- CLRB N/A
- QCLS N/A
- EPS
- CLRB N/A
- QCLS N/A
- Revenue
- CLRB N/A
- QCLS N/A
- Revenue This Year
- CLRB N/A
- QCLS N/A
- Revenue Next Year
- CLRB N/A
- QCLS N/A
- P/E Ratio
- CLRB N/A
- QCLS N/A
- Revenue Growth
- CLRB N/A
- QCLS N/A
- 52 Week Low
- CLRB $2.71
- QCLS $2.50
- 52 Week High
- CLRB $48.90
- QCLS $164.00
- Technical
- Relative Strength Index (RSI)
- CLRB 33.08
- QCLS N/A
- Support Level
- CLRB $2.78
- QCLS N/A
- Resistance Level
- CLRB $3.15
- QCLS N/A
- Average True Range (ATR)
- CLRB 0.25
- QCLS 0.00
- MACD
- CLRB 0.01
- QCLS 0.00
- Stochastic Oscillator
- CLRB 16.83
- QCLS 0.00
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About QCLS Q/C Technologies Inc. Common Stock
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.